About this trial
This study aims to investigate the feasibility of utilizing the SurgDiff surgical difficulty prediction model to assist surgeons in formulating precise surgical plans.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pathological examination confirmed a diagnosis of rectal adenocarcinoma; radical surgery is recommended.
The inferior border of the tumor is ≥1 cm from the dentate line and ≤7 cm from the anal verge;
Preoperative staging was assessed in a stage of c/ycT1-3N0-2M0;
The cardiac, pulmonary, hepatic, renal, and other organ functions are adequate, and the patient can tolerate laparoscopic surgery.
Disqualifiers
Intraoperative exploration is unable to achieve R0 resection or preservation of the anus;
Lateral lymph node dissection is required;
Patients with a history of severe mental illness, immune disorders, or those taking hormonal medications;
Any other circumstances in which the investigator deems it inappropriate for inclusion.
Trial design
Parallel
Treatments tested in this trial
AI-assisted decision-making
Procedure/SurgeryThe SurgDiff model performs a difficulty assessment based on the patient's preoperative MRI scans and clinical data, thereby assisting the surgeon in formulating the surgical plan
Treatment groups
Trial outcomes
Primary outcomes
Mesorectal incomplete rate
Secondary outcomes
Operative conversion rate
Defined as the proportion of cases where laparoscopic total mesoresection (laTME) was converted to open total mesoresection (taTME), or where taTME was converted back to laTME, or where conversion occurred to an open surgical approach during the procedure.
Positive resection margin rate
defined as the presence of cancer cells on the distal rectal resection margin
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: